Oppenheimer analyst Steven Lichtman raised the price target on Medtronic, Inc. (NYSE: MDT) to $147.00 (from $134.00) while maintaining an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Medtronic, Inc. (MDT) PT Raised to $145 at UBSMay 28, 2021 8:29 AM Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development AgreementMay 28, 2021 7:30 AM Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development AgreementMay 28, 2021 7:30 AM Medtronic, Inc. (MDT) PT Raised to $135 at Raymond JamesMay 28, 2021 7:23 AM Medtronic, Inc. (MDT) PT Raised to $149 at Deutsche BankMay 28, 2021 6:43 AM Medtronic, Inc. (MDT) PT Raised to $140 at Wells FargoMay 28, 2021 6:38 AM Medtronic, Inc. (MDT) PT Raised to $143 at CitiMay 28, 2021 5:59 AM Medtronic, Inc. (MDT) PT Raised to $138 at Truist SecuritiesMay 28, 2021 3:55 AM Medtronic, Inc. (MDT) PT Raised to $140 at StifelMay 27, 2021 5:46 PM Medtronic, Inc. (MDT) PT Raised to $146 at Needham & Company, Following EarningsMay 27, 2021 3:45 PM Medtronic (MDT) Tops Q4 Earnings Estimates, Announces 'Largest Ever' R&D Spending to Support GrowthMay 27, 2021 10:20 AM Medtronic (MDT) Tops Q4 EPS by 8c, Offers FY22 Guidance, Raises DividendMay 27, 2021 6:46 AM Medtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend IncreaseMay 27, 2021 6:45 AM